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Barrett’s oesophagus is an acquired metaplastic condition that predisposes patients to the development of 
oesophageal adenocarcinoma, prompting the use of surveillance regimes to detect early malignancy for endoscopic 
therapy with curative intent. The currently accepted surveillance regime uses white light endoscopy together with 
random biopsies, but suffers poor sensitivity and discards information from numerous light-tissue interactions that 
could be exploited to probe structural, functional and molecular changes in the tissue. Advanced optical methods are 
now emerging that are exquisitely sensitive to these changes and hold significant potential to improve surveillance of 
Barrett’s oesophagus if they can be applied endoscopically. The next decade will see some of these exciting new 
methods applied to Barrett’s surveillance in new device architectures for the first time, potentially leading to a long-




Barrett’s oesophagus is an acquired metaplastic condition that predisposes patients to the development of 
oesophageal adenocarcinoma (OAC)1. The progression to cancer occurs through an intermediate stage known as 
dysplasia, which can be of low-grade (LGD) or high-grade (HGD). The cancer risk in non-dysplastic Barrett’s 
oesophagus is estimated to range from 0.1 to 0.5%/year2, but it increases to up to 9% in the presence of LGD3 and it 
is 4 times higher in patients harbouring HGD, compared to patients with LGD4. As the 5-year survival rate for 
oesophageal cancer is just 15%, but improves to 80% in patients with early-stage cancer5,6, major advisory bodies 
recommend that patients with Barrett’s oesophagus undergo routine endoscopic surveillance for signs of dysplasia or 
early carcinoma7–11. Given the steep rise in cancer risk in patients with dysplasia, when LGD, HGD or in-situ 
carcinoma are detected there is indication to treat the early neoplastic lesion endoscopically with curative intent. 
Indeed, data from some retrospective studies indicate that endoscopic surveillance correlates with improved 
survival12,13, although evidence from a case-controlled study14 did not confirm this and data from randomised 
controlled trials is lacking. 
The current standard of care (SOC) for endoscopic surveillance uses high-definition white light endoscopy 
(HD-WLE) to identify suspicious lesions, then histopathological analysis of biopsied tissue for diagnosis 
(Supplementary Figure 1). To mitigate the risk of missing subtle, flat lesions, the protocol includes taking random 
biopsies at four-quadrant positions, in addition to targeted biopsies of visible lesions7. The resulting sensitivity is 40%-
64% with specificity of 98-100%15, but the procedure is costly, time-consuming and prone to sampling error11. The 
potential to improve clinical outcomes by detecting dysplasia with advanced optical methods has driven a great deal of 
research in this area. 
White light endoscopy discards information from a wide range of contrast mechanisms (Figure 1) that can be 
exploited by more advanced optical methods to determine the disease state of tissue. In this review, we use the term 
‘optical method’ to refer to the combination of an underlying contrast mechanism with an endoscope-compatible 
device, which results in a signal that can be used to guide the endoscopist. With demand for endoscopy predicted to 
rise substantially over the next decade16, the unmet clinical need for optical methods with improved diagnostic yield 
and lower device cost / complexity is particularly acute. 
Advanced optical methods are categorised as ‘red-flag’, ‘optical biopsy’ or hybrid. Red-flag methods provide 
wide-field images and if they provide sufficient contrast for dysplasia, can replace the random four-quadrant biopsies 
through improved targeted biopsy. A recent study estimated that using a targeted biopsy protocol alone could reduce 
per-patient biopsy costs from ~£1000 to ~£3017.  Conversely, optical biopsy methods measure a small area of tissue 
with the goal of providing in vivo, real-time diagnosis, which could ultimately replace physical biopsy and enable 
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surveillance and intervention to occur within the same procedure. Hybrid methods, as the name suggests, combine 
red flag and optical biopsy capabilities to identify and diagnose disease in vivo.  
The field of advanced endoscopy has been described in several recent reviews9,15,18,19. Here, we summarise 
the current status of the field with a focus on newly emerging optical methods, considering in particular the impact of 
device architecture on clinical translation. We conclude with a perspective on the potential for improvements in the 
endoscopic surveillance of Barrett’s oesophagus. 
 
Emerging endoscopic device architectures 
 
At present, clinical endoscopic surveillance of Barrett’s oesophagus is performed using a forward-facing trans-
oral endoscope architecture, around which standard endoscopic tools, such as biopsy forceps and treatment devices, 
have been designed. Forward-facing endoscopes require articulation by the endoscopist to ensure complete 
surveillance of the tissue. A key consideration in the development and clinical translation of new optical methods is 
whether this remains the appropriate device architecture. An obvious and naïve approach to advanced endoscopy is 
simply to integrate the new optical imaging method into an existing forward-facing endoscope, to exploit familiarity of 
endoscopists with the presented images and retain access to the usual endoscopic tools. In recent years, research 
groups and commercial companies have taken a more ‘out-of-the-box’ approach, developing a host of alternative 
device architectures that overcome some or all of the limitations of forward-facing endoscopy, namely: low 
magnification; high procedure cost; the need for specialist operators; and restricted angular field of view (Table 1 and 
Figure 2). 
Accessory channel endoscopes, or ‘babyscopes’, enable small-diameter probes to be inserted into standard 
forward-facing endoscopes through the channel that is normally used to introduce tools. They provide enhanced 
image data, often placed in direct contact with oesophageal tissue for optical biopsy methods. Unlike physical biopsy, 
increasing the number of these optical biopsies does not add significantly to procedure cost, however, the endoscopist 
must manually control the position the babyscope, so the results will still be subject to sampling error. In addition to 
this, the physiological movements of the oesophagus due to peristalsis and anatomic vicinity to the heart, make 
stabilization of the microscopic image challenging. In other cases, rather than direct contact, the imaging device 
employs a balloon that is inflated to ensure a fixed distance between the tissue and the central axis of the imaging 
hardware20,21.  
The high procedure cost of forward-facing endoscopy arises from the need for patient sedation in a specialist 
facility with a skilled endoscopist. Unsedated trans-nasal endoscopy (UTNE) provides standard endoscopy 
capabilities (imaging, articulation, insufflation, suction, biopsy) in a slim device that can be used without sedation, as 
the trans-nasal intubation does not involve contact with the root of the tongue and therefore does not trigger the 
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gagging reflex. UTNE has been successfully used for imaging BO and oesophageal dysplasia22–24. Multiple UTNE 
systems are commercially available, including two disposable devices which make reprocessing feasible outside of a 
hospital environment25. Recent studies using UTNE in screening for BO have found it to be comparable to standard 
endoscopy in clinical effectiveness, participation and safety26 and considerably cheaper, especially if implemented in a 
mobile unit instead of a hospital27. Nonetheless, UTNE image quality is currently insufficient for dysplasia detection in 
surveillance setting. 
While UTNE still requires a skilled endoscopist, wireless capsule endoscopes are single-use, pill-shaped 
devices that can be administered by a non-specialist operator. Originally developed for small bowel imaging28, 
wireless capsules have since been developed for the oesophagus29. When surveyed, most patients prefer capsule 
endoscopy to regular endoscopy30, which may improve adherence to surveillance protocols. Capsule endoscopy has 
become the gold standard for the small bowel, but studies in the oesophagus have yielded mixed results31. Wireless 
capsules have several significant limitations in the oesophagus32: the need for a reclined ingestion protocol to 
increase the imaging period during swallowing from seconds to minutes31; difficulty in identifying the capsule location 
for a given image; and the inability to take biopsies during the procedure.  
Tethered capsule endoscopes retain the benefits of wireless capsules while addressing several of their 
limitations in the oesophagus by using a cord to control the capsule’s position33. The tethered capsule is swallowed by 
the patient in an upright position, then imaging is performed while it is pulled back up from the stomach. The tethered 
architecture eliminates the risk of capsule retention and opens up the possibility of capsule re-use, which could lower 
per-procedure costs34.  A tethered capsule architecture for Barrett’s surveillance is currently in clinical trials35.  
Finally, increased inspection time has been associated with an increased HGD/OAC detection rate in HD-
WLE Barrett’s surveillance36, however, it is unclear whether this relates to longer time spent by the endoscopists in 
characterizing lesions detected during the examination. Inspection time is affected by the need of careful articulation 
of the endoscope to bring the entire luminal surface within the 160-180° forward-facing field of view. Wide angle 
endoscopes37 with a 330° field of view have been successfully demonstrated in the colon. One study found that this 
decreased the colonic adenoma miss rate from 41% to 7%38 compared to standard forward facing devices although 
this was not confirmed in a recent randomised study39. Wide angle or stereoscopic devices40, which allow 3D 
reconstruction, have yet to be implemented in the upper gastrointestinal tract but may improve surveillance. 
 
Optical endoscopic methods used in clinical practice for BO surveillance 
 
Several advanced optical methods, such as acetic acid chromoendoscopy, narrow band imaging and confocal 
laser endomicroscopy, have made their way into clinical use in some centres. Still, endoscopic practice varies 
significantly across countries and within the same country, and use of these advanced optical methods is often 
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restricted to tertiary referral centres delivering endoscopic treatment to a high volume of dysplastic patients. These 
methods have been extensively reviewed elsewhere19,41, so we will only briefly summarise them here. For reference, 
Table 2 and Supplementary Figure 2 show the current evidence, recommendation status, as well as key 
advantages and disadvantages of these methods. A recent meta-analysis by the American Society for Gastrointestinal 
Endoscopy (ASGE) suggest that to be recommended for targeting biopsy, a new technology should achieve at least 
90% sensitivity, 80% specificity and 98% negative predictive value18. 
Chromoendoscopy enhances contrast through topically applied dyes. Acetic acid eliminates the superficial 
mucosal layer and then causes acetylation of cellular proteins, resulting in whitening that highlights surface patterns. 
In case of neoplastic Barrett’s, this is rapidly followed by focal erythema caused by vascular congestion in stromal 
capillaries, which is revealed as focal redness as loss of acetowhitening occurs17. These reactions are used to guide 
targeted biopsies and increase the yield of dysplasia, meeting the ASGE performance thresholds18,42. Methylene blue 
chromoendoscopy has also been extensively investigated, but there are concerns regarding possible carcinogenic 
effects of the dye43. Meta-analyses have found it to be inferior to WLE44 and acetic acid chromoendoscopy18. It is 
therefore likely that acetic acid will become the standard conventional chromoendoscopic method for BO surveillance. 
Virtual (also known as electronic or optical) chromoendoscopy improves contrast by modifying the endoscope 
hardware or software. This avoids the challenges of working with dyes, such as increased procedure time for dye 
administration and potential for adverse effects caused by the dye. Hardware modifications reported to date usually 
involve adapting the light source to focus on blue and green wavelength bands, where the haemoglobins are strongly 
absorbing, providing contrast based on changes in the tissue vasculature41. Narrow band imaging (NBI) is the most 
widely established and also meets the ASGE thresholds18. NBI highlights the capillary network of the superficial 
mucosa and the operator classifies the disease state of the tissue based on altered vascular and mucosal patterns 
associated with dysplasia45. Blue laser imaging (BLI) is a similar technology that has also been tested in patients (in 
vivo, comparative study, n=39 patients)46 and is under evaluation in Barrett’s oesophagus47. Software-based virtual 
chromoendoscopy methods48,49 use proprietary image processing algorithms to improve the contrast of mucosal and 
surface vessel patterns in the GI tract50. While there is not currently sufficient data for advisory bodies to make 
recommendations18, clinical studies have shown that software-based approaches compare well to acetic acid 
chromoendoscopy (in vivo, prospective randomized pilot study, n=57)51. These early findings will need to be confirmed 
with large randomised controlled trials. Virtual chromoendoscopy has significant advantages in being label-free and 
easily applied in any WLE device architecture, including UTNEs25 and capsules52,53, so now has widespread 
availability. 
While chromoendoscopy relies on light reflected from tissue, fluorescence imaging uses emission of a longer 
wavelength (or ‘redder’ colour) of light after illumination of the tissue to provide added contrast for dysplasia in 
endoscopic surveillance. Several structural and metabolic molecules intrinsic to tissue, such as collagen and NADH, 
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are fluorescent. Dysplastic tissue exhibits lower ‘autofluorescence’ than surrounding healthy tissue54. 
Autofluorescence imaging (AFI) has high sensitivity for dysplasia, but low specificity because inflammation also 
reduces tissue autofluorescence55. AFI is implemented by adding filters to the light source and detector on a standard 
endoscope, so has been combined with HD-WLE as well as virtual chromoendoscopy in endoscopic trimodal imaging 
(ETMI) in an effort to increase specificity. Trials to date have yielded mixed results 56,57; it remains unclear whether AFI 
truly adds to the already improved performance of NBI.  
In addition to the intrinsic fluorescence, intravenous fluorescein (a fluorescent dye) can be used to highlight 
microvasculature and tissue structures to detect dysplasia. This is commonly examined using confocal laser 
endomicroscopy (CLE), which produces depth-sectioned, high magnification and resolution images, which can be 
used to spot changes in cell morphology associated with dysplasia, yielding high sensitivity and specificity18. An 
endoscope-based CLE system (eCLE) was recommended by the ASGE18, but requires a dedicated endoscope that is 
no longer on the market. A ‘babyscope’ probe-based CLE (pCLE) with lower resolution and limited depth sectioning, 
which can be inserted through the working channel of a standard forward facing endoscope is available. Clinical trial 
results to date indicate that pCLE can be used to identify neoplasia but is not yet sufficient to replace random biopsy58. 
Neither fluorescence approach is available in UTE format as yet; the feasibility of incorporating fluorescence imaging 
into capsule endoscopes is being explored59. 
 
Emerging optical methods for endoscopic BO surveillance: what is on the horizon? 
 
While existing advanced endoscopy methods have shown potential for improving the identification of 
dysplasia during BO surveillance, a number of exciting recent advances have been made in optical imaging that could 
address outstanding limitations in sensitivity and specificity, ultimately reducing the high miss rate15,60 (Table 3 and 
Supplementary Figure 3). Given the aforementioned challenges with the use of dyes and the other excellent recent 
reviews of optical molecular imaging61, we will concentrate here on label-free methods. 
 
Interrogating disordered tissue structure 
 
HD-WLE interrogates disordered tissue structure by presenting images of macroscopic abnormalities on the 
epithelial surface. Several recent advances have been made that allow endoscopists to probe cross-sectional 
information, up to several millimetres deep. Optical coherence tomography (OCT) can be thought of as ‘optical 
ultrasound’, with contrast derived from changes in refractive index rather than impedance mismatch. OCT uses 
scanning low-coherence interferometry to construct 3D reflectance images that reveal changes tissue microstructure 
arising due to variations in light scattering62, giving excellent contrast for dysplasia63. Endoscopic applications of OCT 
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were made feasible by the shift from time-domain OCT to optical frequency domain imaging (OFDI), which 
significantly increased data acquisition rates. 3D images of the entire oesophagus can be acquired using an inflatable 
balloon babyscope device architecture, compatible with forward-facing endoscopes20, or a rotating probe housed in a 
tethered capsule endoscope33. Both helical, luminal imaging approaches can be referred to as volumetric laser 
endomicroscopy (VLE). VLE has been successfully correlated with histology in BO patients64 (ex vivo, feasibility study, 
n=14 matched resection specimens) and detects oesophageal neoplasia in vivo63 (in vivo, patient series, n=6 
patients). One challenge with VLE is enabling guidance of tissue biopsy, which is not compatible with the existing 
device architectures; a combination of VLE and laser cautery has been shown to safely mark regions of interest for 
later biopsy under HD-WLE guidance65 (in vivo, pilot study, n=22 patients). A second challenge remains with image 
interpretation; an experienced OCT endoscopist is currently needed, limiting widespread deployment. Automated 
image analysis is being investigated to alleviate this burden and bring the method closer to the clinic66,67. 
In addition to providing contrast for OCT, variation in light absorption and scattering from tissue can be 
recorded as a function of wavelength or angle. Diffuse reflectance spectroscopy (DRS), also called elastic scattering 
spectroscopy (ESS), illuminates the tissue with a standard white light source, but instead of collecting an image of the 
oesophagus using a camera, changes in the colour of the light arising from absorption and scattering events in the 
superficial layers of the tissue are measured with a spectrometer, a device that disperses white light into its 
component colours. Contact (ESS)68 and fixed-distance (DRS)69 babyscope probes can differentiate between healthy 
and dysplastic tissue in the oesophagus, though are typically restricted to point-based measurements rather than 
endoscopic imaging.  
Taking the concept a step further, light scattering spectroscopy (LSS) singles out reflected light that has only 
scattered once in tissue. The benefit of this approach is that LSS measurements can be directly linked to tissue 
morphology via physical Mie scattering theory, enabling quantitative measurements of the size and density of cell 
nuclei, which is associated with disease state70. An early LSS study achieved 90% sensitivity and specificity for 
oesophageal dysplasia71 (in vivo, single centre pilot study, n=13 patients, n=76 sample positions) with a babyscope 
contact probe, but unwanted variations in probe-tissue separation led to challenges for interpretation. Hardware 
developments overcame this limitations to enable 8 cm segments of oesophagus to be mapped with 92% sensitivity 
and 96% specificity72 (in vivo, single centre pilot study, n=9 patients, n=95 biopsies), showing potential for this to 
become a useful red-flag tool for guiding targeted biopsies in Barrett’s surveillance. Angle-resolved low coherence 
interferometry (a/LCI) also looks at singly-scattered light but probes the angular scattering distribution of just a single 
colour of light. a/LCI has been shown to identify dysplasia (including LGD) with 100% sensitivity and 84% specificity in 
vivo73 (in vivo, 2 centre pilot study, n=46 patients, n=172 sample positions) and a negative predictive value of 100%.  
Although DRS, LSS and a/LCI were originally point measurement methods, the ability to provide 2D maps that 
co-register with HD-WLE or other images of tissue anatomy has now been demonstrated69,74, although not yet tested 
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in vivo.  There are also phase and polarisation-sensitive endoscopic methods on the horizon that derive contrast from 
scattering and present wide-field images75,76. While VLE is the most advanced method for interrogating microstructure 
in terms of clinical translation, if their performance remains high in randomised controlled trials, DRS, LSS and a/LCI 
have potential to become valuable tools to guide targeted biopsy.  
 
Interrogating abnormal tissue function and metabolism 
 
Virtual chromoendoscopy has been successful in improving targeted biopsy based on changes in tissue 
vasculature, but only interrogates superficial epithelial changes. OCT has shown exciting possibilities for cross-
sectional imaging of tissue function, using measurements of blood flow to highlight the vasculature77,78, although these 
have yet to be clinically validated. Another method that provides cross-sectional vascular information is photoacoustic 
endoscopy (PAE), which uses optical excitation of tissue to generate ultrasound79. The benefit of this approach is that 
highly optically absorbing molecules in tissue, such as haemoglobins, can be resolved at far greater penetration depth 
than is available from exclusively optical imaging. PAE could therefore directly provide high resolution cross-sectional 
virtual chromoendoscopy at centimetre depths, allowing visualisation of vascular patterns associated with dysplasia. 
PAE devices using a similar helical scanning implementation to OCT80–82 have been applied in rabbit oesophagi83, but 
further development is needed to increase radial resolution and acquisition speed, as well as to address challenges 
with image interpretation (similar to those of OCT). Recent successful studies using photoacoustic imaging in breast 
cancer diagnosis and other areas84 suggests that application of PAE in Barrett’s surveillance may yet yield valuable 
information, potentially in combination with OCT and other advanced methods81. 
Using a contrast mechanism already applied in the clinic, time-resolved assessment of tissue 
autofluorescence may overcome the present challenge of poor specificity in the interpretation of AFI. Changes in 
autofluorescence intensity, as measured by standard AFI endoscopes, can be confounded by surface irregularities 
and non-uniform illumination. Fortunately, measuring the lifetime of the fluorescence signal, rather than its absolute 
intensity, avoids these confounding factors85. Fluorescence lifetime microscopy (FLIM) is able to map changes in local 
tissue microenvironment and has shown promise in detection of cancers in ex vivo and in vivo studies85. For many 
years, the clinical translation of FLIM was limited by the size, cost and complexity of the instrumentation and the need 
for long integration times due to weak signals. A 2003 study of point-based fluorescence lifetime measurements found 
sensitivity and specificity for HGD of less than 60% using time resolved fluorescence86 (in vivo, single centre pilot 
study, n=37 patients, n=108 fluorescence decay profiles). More recently, however, compact diode-pumped laser-
based excitation sources and time-gated methods have addressed instrumentation limitations87 meaning wide-field 
FLIM endoscopes with near-video rate acquisition (~2Hz)88–90 are now available. While these have been used in 
vivo88,91 they have yet to be applied to Barrett’s surveillance and may yield improved performance in this context.  
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Complementing wide-field FLIM approaches, multi-photon microscopy (MPM) provides an autofluorescence-
based alternative to pCLE.  MPM is a scanning, optical sectioning, imaging approach in which fluorescence is spatially 
delineated using non-linear optical excitation. Ex vivo MPM of fresh punch biopsies can successfully distinguish 
squamous mucosa, gastric columnar mucosa and intestinal metaplasia92 (ex vivo, n=25 patients, n=35 biopsies) 
suggesting that MPM could be used to identify dysplasia. MPM endoscopes are being developed and can incorporate 
additional features from microscopy such as super-resolution imaging93. Although MPM is at a very early stage of 
development, it holds potential to perform high magnification, depth-sectioned, label-free endomicroscopy as part of 
Barrett’s surveillance. 
 
Interrogating bulk molecular composition 
 
Changes in bulk molecular composition can be determined using the spectral ‘fingerprint’ measured through 
Endoscopic Raman Spectroscopy (ERS), which is typically classified based on machine-learning methods that use a 
training set of spectra where the disease classification is known from histopathology analysis94. ERS is sensitive to the 
abundance of molecular bonds, primarily lipid, protein and nucleic acid content in tissue. ERS probes are typically 
introduced through a babyscope into a standard forward-facing endoscope and positioned directly on a suspicious 
region of tissue to provide a point-based measurement.  
The low intensity of Raman signals has been a hurdle for ERS, historically resulting in very slow data 
acquisition. Nonetheless, Bergholt et al. recently demonstrated an ERS babyscope system, including a classification 
algorithm based on a Raman library of >12000 spectra, that could differentiate between columnar lined epithelium, 
non-dysplastic BO or HGD, in real time (0.2 sec), passing this information to the endoscopist using auditory 
feedback95 (in vivo, pilot study, n=77 patients, sensitivity 87.0%, specificity 84.7%). Trans-nasal image-guided Raman 
spectroscopy has also been demonstrated96. Alternatively, Coherent Anti-stokes Raman Spectroscopy (CARS), which 
uses multiple photons to probe specific regions of the spectral fingerprint, has been suggested as a way to overcome 
the low Raman intensity and several prototype endoscopes have been developed, despite challenges associated with 
non-linear effects in fibres and the design of miniature optics97,98. Precision remains a challenge for ERS and ECARS, 
due to pressure-based signal variation, but prospective randomized multicentre trials are underway95 and further 
devices are under development99. Raman spectroscopy is thus a promising method that could provide point 





The recent advances highlighted above suggest that the intrinsic optical interactions with tissue have the 
potential to improve the diagnostic yield of Barrett’s surveillance. Naturally, combining several of these into a single 
device architecture could have added benefits, giving access to structural, functional and molecular information 
simultaneously. For example, a recent pilot study with an intraoperative fibre probe combining DRS, ERS and 
fluorescence spectroscopy achieved 100% sensitivity and 93% specificity for several cancers100.  
Achieving a successful combination, however, requires careful optical design and often complex 
instrumentation. One promising route to overcoming this challenge may lie in the use of hyperspectral imaging (HSI), 
where the light illuminating the tissue and being imaged is dispersed into its component colours, or rapidly modulated. 
NBI is a simple example of this, where restricting illumination to two wavelengths highlights the vasculature in tissue 
due to strong haemoglobin absorption. HSI goes further, recording 10s or 100s of colours at every pixel in an 
endoscopic image, which can then be processed using machine-learning methods to resolve reflectance (e.g. NBI, 
BLI, DRS), fluorescence (AFI) or Raman (ERS) information into separate images. HSI has shown potential for aiding 
cancer diagnosis in a range of organ sites, including the oesophagus101, although has yet to be demonstrated through 
in vivo trials in Barrett’s surveillance. HSI hardware is often bulky and slow; optimisation of the HSI hardware, for 
example using compact spectrally resolved detector arrays102, may assist in the future with real-time clinical 
application.  
Introducing cross-sectional methods into such endoscopes adds a further challenge, particularly if helical 
scanning implementations are needed, as these typically require further endoscopist training to develop specialist 
expertise for interpretation. If true optical biopsy is to be achieved, cross-sectional information will be vital. The 
addition of scattering measurements that exploit other dimensions of light than colour, such as phase and 




Translational outlook for new optical methods 
 
 
Novel optical imaging methods that probe structural, functional and molecular information in tissue hold 
significant potential to improve BO surveillance endoscopy. Clinical translation of these emerging optical methods, 
however, faces many challenges. The most appropriate device architecture for implementation of the optical method 
must first be identified. Next, the resulting endoscopic instrument must undergo technical and biological validation in 
phantoms, preclinical models and clinical trials to ensure performance and safety standards are met103. Several 
challenges can be encountered at this stage. For technical validation, the lack of calibration standards and accepted 
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internal exposure limits for optical diagnostic methods makes it difficult to assess the risks of potential thermal 
damage or photoallergic reactions for a new device104. Testing in ex vivo tissue does not provide an appropriate 
reference in this regard, since blood flow will dissipate heat. Furthermore, for biological validation, the optical 
properties of tissue can change markedly when examined ex vivo, which may limit the utility of subsequent in vivo 
findings92,105. Given the limited number of studies detailing the nature of changes in light-tissue interactions during the 
development of dysplasia, particular benefit for biological validation may be derived from further ex vivo and in vivo 
analysis of oesophageal tissue in different disease states. 
Clinical trials at expert research centres with enriched populations or complex protocols may also bias 
findings, which can lead to disappointing results once deployment is more widespread56,57. For example, ASGE 
recommendations for use of acetic acid chromoendoscopy, NBI and eCLE for targeted biopsy assume the 
endoscopist has specialist training in image acquisition and interpretation for these methods. The use of 
histopathological diagnosis as the gold standard for evaluation of a new optical endoscopic device can also be 
confounding, since it itself is prone to sampling and interpretation errors11,106. Ideally, biopsies would be taken under 
guidance of a new optical method and subjected to consensus histopathology to minimise such errors. The alternative 
is to establish longitudinal studies that relate early-stage imaging parameters to late-stage clinical outcomes, which is 
extremely costly. Once devices and specialists are available across multiple sites, metrics to interpret the images must 
be developed and perfected, often by consensus of an expert group. This complex development process requires 
strong multidisciplinary collaboration, including expertise from medicine, engineering, physics, biomedical sciences, 
computer science and mathematics. Clear and open communication between those developing new endoscopic 
devices and those who will ultimately operate them is paramount. 
The emerging optical methods reviewed here aim to either increase the contrast of wide-field ‘red flag’ 
endoscopic surveillance, for improved targeting of physical biopsies, or to provide an ‘optical biopsy’ that could yield 
diagnostic information directly during the endoscopic procedure. Enhancing the existing red-flag forward-facing 
endoscopy could be achieved through the addition of light scattering spectroscopy72, but further clinical studies are 
needed to establish potential for improved BO surveillance. Hyperspectral endoscopy has the potential to enable a 
truly multi-modal red-flag and is the subject of ongoing work across a number of centres.  
The majority of optical methods reviewed provide an optical biopsy. Several spectroscopic methods (DRS, 
LSS, a/LCI, ERS, ECARS) are compatible with forward-facing endoscopy using a babyscope and have the potential to 
be automated to give a fast real-time binary feedback to the endoscopist73,95. As their application becomes more 
widespread, the acquisition of more data will enable refinement of the automated classification algorithms, further 
improving sensitivity and specificity. Imaging methods applied for optical biopsy, such as CLE and MPM, also hold 
promise, particularly if they are able to achieve adequate depth sectioning to yield high quality images for 
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interpretation by histopathologists. Given the restricted field-of-view of such methods, they remain reliant on a high 
contrast red-flag endoscopy to achieve their diagnostic potential. 
Hybrid approaches that combine red-flag and optical biopsy information, as well as structural and functional 
information, have also been demonstrated. Photoacoustic endoscopy is at an early stage, while volumetric laser 
endomicroscopy (VLE) is the most mature of the emerging methods described in this review, with a commercial 
system already available20. Furthermore, it has been demonstrated in both babyscope balloon and tethered capsule 
device architectures. If contact between the capsule device and the lumen can be maintained, VLE is able to capture 
high-resolution volumetric images of the entire oesophagus, an interesting niche. Although interpretation is currently 
performed offline, the development of automated diagnosis algorithms66, accelerated by recent advances in machine 
learning coupled with increasingly inexpensive computing power, offers the possibility of a real-time computer-aided 
diagnosis. Such information could be combined with immediate laser cautery marking of suspicious lesions65. Though 
at present a standard forward-facing endoscope would still be required for physical biopsy and therapeutic 
intervention, the comprehensiveness, simplicity, and apparent achievability of VLE is exciting.  
In summary, an ideal BO endoscopic surveillance method would perform comprehensive investigation of the 
oesophagus with high sensitivity and specificity for dysplasia. It should allow for use of endoscopic tools for marking 
and biopsy if necessary. It should also be possible to implement with minimal additional training of endoscopist 
operators and image interpreters. To achieve widespread deployment in healthcare systems, no significant change to 
procedure times or costs should be made; ideally these would be reduced. If possible, availability of endoscopy to BO 
patients should be increased, for example by enabling deployment by non-specialist operators in primary care 
centres, and physical discomfort with the procedure should be decreased, to improve compliance with surveillance 
programmes.  
Though several advanced endoscopy methods have been recommended for routine use in Barrett’s 
oesophagus, histological assessment of HD-WLE targeted and random biopsies is still the standard-of-care. Many 
emerging methods combine a contrast mechanism and device architecture to achieve some of the aforementioned 
requirements, but fall short of providing the ideal solution. Continuing advances in hardware and software are allowing 
endoscopic application of optical methods developed for other indications. The next decade will see some of these 
exciting new methods applied to Barrett’s surveillance in new device architectures for the first time, potentially leading 





4QB 4-quadrant biopsies 
a/LCI angle-resolved low coherence interferometry 
AA Acetic Acid 
ACG American College of Gastroenterologists9 
AFI autofluorescence imaging 
AGA American Gastroenterology Association107 
ASGE American Society for Gastrointestinal Endoscopy18 
BO Barrett’s Oesophagus 
BSG British Society of Gastroenterologists7 
CARS coherent anti-Stokes Raman spectroscopy 
DRS diffuse reflectance spectroscopy 
eCLE endoscope-based confocal laser endomicroscopy 
ERS endoscopic Raman spectroscopy 
ESGE European Society of Gastrointestinal Endoscopy8 
ESS elastic scattering spectroscopy 
ETMI endoscopic trimodal imaging 
FICE Fujicon Intelligent Colour Enhancement 
FLIM fluorescence lifetime imaging 
HD-WLE high-definition white light endoscopy 
LSS light scattering spectroscopy 
MB methylene blue 
MPM multi-photon microscopy 
MSI/HIS multi-/hyper- spectral imaging 
NBI narrow band imaging 
OCT optical coherence tomography 
OFDI optical frequency domain imaging 
OMI optical molecular imaging 
PAE photoacoustic endoscopy 
pCLE probe-based confocal laser endomicroscopy 
SOC standard of care 
TRF time resolved fluorescence 





Figure 1. Contrast mechanisms.  An optical contrast mechanism consists of three elements: illumination, interaction, 
and detection of light. By carefully controlling the properties of the light illuminating the tissue (left) we can probe 
specific light-tissue interactions (right). These include reflection, absorption, elastic/inelastic scattering and 
fluorescence. Advanced endoscopic imaging modalities use these interactions as a source of contrast for detection of 
dysplasia (centre). Information about the interaction is encoded within the properties of the output light: the 
wavelength, the distance between peaks in the wave; the polarisation, the direction in which the wave oscillates; the 
phase, the point in the cycle of the wave; and the intensity, the power within the wave. Detection of these properties 
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* optoacoustic imaging detects sound out
Contrast Mechanism
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Table 1. Endoscopic device architectures. 
** Theoretically most combinations of contrast mechanism and device type are possible. Here we give the contrast mechanisms that are most compatible with the advantages and disadvantages of the device 
architecture. 
*** Image type is again dependent on contrast mechanism. Here we give the image types for the most compatible contrast mechanisms for the device architecture. 
Schematics of each device architecture are shown in Figure 2. 
 





e.g. Olympus, Pentax, 
Fuji 




+ Wide variety of tools for biopsy, washing, marking 
+ Articulation 
- Endoscopist must articulate to survey entire surface 
WLE, Chromoendoscopy, NBI, 





e.g. Olympus, Pentax, 
Fuji 
Wide (typically 140° 
luminal view) 
+ Improved patient tolerance and no sedation required 
+ Articulation 
+ Shorter, less costly procedure 
- Endoscopist must articulate to survey entire surface 
- Lower quality image*, narrower working channel inappropriate for 
interventions, poorer suction and air function and smaller biopsy 
capabilities compared with trans-nasal endoscopes 
*unsuitable for Barrett’s surveillance 
WLE, NBI En-face, luminal 108 
Babyscope  
E.g. Contact Probe Mauna Kea Cellvizio® 
Narrow (10s – 100s 
microns) 
+ Compatible with insertion through working channel of standard 
endoscopes 
- Must be used alongside standard endoscope for articulation, 
washing, biopsy, marking 
- Contact with lumen must be carefully controlled 
- Small FOV 
pCLE, ERS, ESS/DRS, a/LCI, 
MSI/HSI, FLIM, MPM, PA, 
Polarimetry 
Spectrum, en-face 109 
Balloon Based NinePoint NvisionVLE® Volumetric 
+ Controlled withdrawal 
+ Potential for cautery marking capability 
+ Compatible with insertion through working channel of standard 
endoscopes 
+ Allows full volumetric imaging of oesophagus 
- No biopsy, washing capabilities 
- Contact with lumen must be carefully controlled 
OCT/VLE/OFDI Volumetric 20,21 
Wireless Capsule Given Imaging PillCam® ESO series 2 x 169° (ESO2) 
+ No sedation required 
+ Can be implemented in primary care 
+ Potential for low cost if reusable 
- One shot (cannot return to suspicious lesions) 
- No biopsy, washing, marking capabilities 
- Long delay for capsule to pass (8 – 10 hours) 
- No control over motion 
- Contact with lumen must be carefully controlled 
WLE, NBI, MSI/HSI, Polarimetry En-face, luminal or circumferential 
29,30,11
0 
Tethered Capsule No commercial devices Volumetric 
+ No sedation required 
+ Can be implemented in primary care 
+ Potential for low cost if reusable 
+ Controlled withdrawal 
+ Potential for cautery marking capability 
+ Immediate removal of capsule 
+ Allows full volumetric imaging of oesophagus 
- No biopsy, washing capabilities 
- Contact with lumen must be carefully controlled 
OCT/VLE/OFDI Volumetric 35 
Wide Angle EndoChoiceFuse (330°) Extra Wide (>140°) 
+ Familiarity 
+ Wide variety of tools for biopsy, washing, marking 
+ Articulation 
+ Wide FOV allows viewing of entire lumen with minimal articulation 
- Increased cost 
WLE, Chromoendoscopy, NBI, 





Figure 2. Schematic representations of the endoscopic device architectures listed in Table 1. 
A: Forward Facing (Trans-oral) 
B: Forward Facing (Trans-nasal) 
C: Babyscope E.g. Contact Probe 
D: Balloon Based 
E: Wireless Capsule 
F: Tethered Capsule 









Table 2. Advanced optical methods in clinical use for endoscopic BO surveillance. 
 
Example images for each method are shown in Supplementary Figure 2. 
* cannot be advocated or discouraged at this time 
 

























HD-WLE + 4QB 
targeted biopsies and 
histopahtology 
• Widely available 
• Well established 
• Prone to sampling error11 




15      
Chromoendoscopy 
• Inexpensive 
• Widely available 
• AA has shown high sensitivity and specificity 
for detecting dysplasia18 
• Potential toxicology issues43 (MB) 
• Increase in procedure time18 
• Low inter-observer agreement 
• No current procedural terminology for billing and 
reimbursement18 
















(e.g. NBI, BLI) 
 
• Ability to visualise mucosal and vascular 
patterns 
• Widely available 
• Ease of use 
• High sensitivity and specificity for detecting 
HGD112,113 
• Reduced number of biopsies114 
• No universal classification criteria until recent BING criteria45 
• Low inter-observer agreement 
• Low sensitivity for LGD115 
 
0.94218 0.97518    *  
Software-based Virtual 
Chromoendoscopy 
(e.g. FICE, iSCAN) 
• No additional hardware costs • Lack of data 0.83
51 




• Easy to combine with NBI and WLE 
• Many studies biased by comparison with substandard 
WLE116 








• Reduced false positive rate relative to AFI 
alone 
• Useful in tertiary referral centres56 but not in community 
practice57 0.805





• Probe can be inserted through working 
channel of standard endoscope 
• Close to in-vivo histology 






• Close to in-vivo histology • Requires dedicated endoscope (in contrast to pCLE) • Often uses exogenous contrast (fluorescein) 0.904




Table 3. Emerging optical methods for endoscopic BO surveillance. 
 
Example images for each method are shown in Supplementary Figure 3. 
 
Blue: Exogenous contrast 
Red: Interrogating disordered tissue microstructure 
Green: Interrogating abnormal tissue function and metabolism 
Purple: Interrogating bulk molecular composition 
Orange: Multimodal methods 
 
























































Optical Molecular Imaging 
(OMI) 
Exogenous fluorophores 
conjugated to targeting moieties 
(lectins, peptides, antibodies, 
affibodies, enzymes) that 
targeting intracellular and 
extracellular proteins and 
enzymes 
Biochemical    
+ Specificity 
- Exogenous contrast 
- Surface images 
- Cost 
In vivo trials in BO61. 
Potential to be translated for 
wide field surveillance. Awaiting 
further in vivo trials. 
Optical Coherence 
Tomography/ 









   
+ High resolution 
+ Depth sectioning 
+ Endogenous contrast 
- Large image datasets 






Light Scattering Spectroscopy 
(ESS/DRS/LSS) 





   
+ Depth penetration 
+ Endogenous contrast 
- Spectrum rather than image 
In vivo trials in BO (single centre 
pilot study, n=9 patients, n=95 
biopsies)72. 
No trials published in last 10 
years. 
Angle-resolved Low Coherence 
Interferometry 
(a/LCI) 
Nuclei Increase in nuclear size    
+ High sensitivity and specificity in 
pilot study 
+ Endogenous contrast 
- Tissue orientation can affect 
results 
 In vivo pilot study in BO (2 
centre pilot study, n=46 patients, 
n=172 sites)73. 
Combination with OCT. Clinical 
trials likely. 





   + Endogenous contrast 
+ Instrumentation challenges 
No trials in BO. 






(NAD(P)H, haemoglobin) Vasculature    
+ Volumetric images 
+ Endogenous contrast 
- Instrumentation challenges 
- Limited resolution at present 
- Long acquisition times 
In vivo imaging of oesophagus 
in animals83. No trials in BO 
Awaiting application to BO. 
Fluorescence Lifetime Imaging 
(FLIM) 
Endogenous fluorophores 
(NAD(P)H, flavins, collagen, 
elastin, phenylalanine, 
tryptophan, tyrosine, melanin). 
Biochemical, 
microenvironment 
(pH, [02], [Ca2+]) 
   
+ More robust than traditional AFI 
+ Endogenous contrast 
- Safety of UV illumination  
- Long acquisition times 
 Ex vivo trials (TRF) (single 
centre pilot study, n=37 patients, 
n=108 fluorescence decay 
profiles)86. 




(NAD(P)H, flavins, collagen, 
elastin, phenylalanine, 
tryptophan, tyrosine, melanin). 
Cell type    
+ Depth sectioning 
+ High resolution 
+ Endogenous contrast 
- Requires high illumination 
intensity 
 Ex vivo trials in BO (n=25 
patients, n=35 biopsies)92. 




Specific molecular groups (e.g. 
C-C proteins, C-C ring of 
phenylalanine, C-C of lipids, C-N 
and N-H of proteins, CH2 of 
lipids, C=C of porphyrins, C=0 of 
proteins and lipids) 
Biochemical    
+ Detailed biochemical information 
+ Algorithms have been developed 
+ Multicentre trials underway 
- Endogenous contrast. 
- Spectrum rather than image 
- Repeatability has been 
questioned 
- Validation using ex-vivo tissue is 
difficult 
 In vivo trials in BO (pilot study, 
n=450 patients)95. 
Potential to be translated if 
repeatability can be confirmed. 
Awaiting multicentre trials. 
Coherent anti-Stokes Raman 
Spectroscopy 
(CARS) 
Specific molecular groups (see 
ERS) Biochemical    
+ Detailed biochemical information 
+ Increased sensitivity compared 
to ERS 
- Instrumentation challenges 
- Requires high illumination 
intensity 
No trials in BO. 
Awaiting further device 
development. 





lesions    
+ Simple 
+ Compact 
+ Endogenous contrast 
- Surface images 
No trials in BO. 
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